News & Events about Greenwich Lifesciences Inc.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update. SABCS...
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) CEO Snehal Patel acquired 3,000 shares of the stock in a transaction that occurred on Friday, October 14th. The stock was acquired at an average price of $9.75 per share, for a total transaction of $29,250.00. Following the transaction, the chief...
Business Wire
5 months ago
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the Company), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: Phase III clinical...
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) CEO Snehal Patel acquired 6,774 shares of Greenwich LifeSciences stock in a transaction on Thursday, June 2nd. The shares were purchased at an average cost of $7.38 per share, for a total transaction of $49,992.12. Following the acquisition, the ...
Ticker Report
9 months ago
Greenwich LifeSciences, Inc. (NASDAQ:GLSI Get Rating) insider Frank Joseph Daugherty bought 1,000 shares of the firms stock in a transaction on Monday, April 25th. The stock was purchased at an average cost of $16.25 per share, with a total value of $16,250.00. Following the ...